TP53 is a gene that normally regulates cell growth and division. Alterations to it may induce a proliferative advantage and confer an aggressive phenotype. In breast cancer, we observed a poor correlation (rs = 0.17) between P53 expression and proliferative activity evaluated as [3H]-thymidine ([3H]-dT) labeling index and an independent prognostic relevance of the two variables. We used a double-labeling technique to simultaneously evaluate the fraction of P53positive and [3H]-dT-labeled cells to analyze the degree of association between the two markers on individual cells in order to understand their biological significance. The study was performed on a series of 44 P53-positive (P53+) breast cancers. Histological sections were immunostained for P53 with monodonal antibody (MAb) PAbl801 and then prooessed 9 9
Introduction
The TP53 gene codes for a nuclear phosphoprotein that is normally expressed at very low levels of all human cells and is able to regulate cell growth and division. Experimental data indicate that the TP5 3 gene is the most commonly altered tumor-suppressor gene in human tumors (1, 2) . Its inactivation plays a major role in cell immortalization and transformation in vitro and is involved in the development of several human tumor types. Therefore, it probably represents a relatively early event in progression (3) (4) (5) . In addition, TP53 alterations induce a proliferative advantage and confer a particularly aggressive phenotype.
The correlation between the immunohistochemical detection of the P53 mutant protein and the presence of mutations in the p53 gene has been analyzed and demonstrated for several tumor types (6, 7) . Moreover, mechanisms other than gene alterations can induce P53 inactivation and, subsequently, protein accumulation ' Supported by grants from the Consiglio Nazionale delle Ricerche (Special Project ACRO, no. 94.01258.PF39), from the Minister0 della Sani d , and from the Associazione Italiana per la Ricerca SUI Cancro (AIRC).
Correspondence to: Rosella Silvestrini, PhD, Istituto Nazionale Tumori, Oncologia Sperimentale C, Via Venezian 1, 20133 Milan, Italy. for autoradiography. A weak direct relation between P53 positivity and [3H]-dT incorporation (rs = 0.4) was observed on the overall series of P53+ tumors and was maintained in subgroups defined by several biological and pathological features, except for estrogen receptor-negative tumors. The simultaneous presence of P53 expression and [3H]-dT incorporation was directly and significantly proportional to the fraction of S-phase cells of the tumor (rs = 0.7). Conversely, the fraction of cells expressing only P53 was inversely related to cell proliferation (rs = -0.66). These fmdings support the hypothesis that P53 has biological functions other than cell cycle regulation. (JHistochem Cytochem @:999-1003,1995) KEY WORDS: Double labeling; P53 expression; Cell proliferation; Human breast cancer. (8, 9) . Such findings and the recent availability of reagents such as the monoclonal antibody (MAb) PAbl801, which can detect the expression of mutant and wild-type PS3 proteins on paraffinembedded material, have allowed analysis of the biological and clinical roles of PS3 accumulation in substantial series of patients with different tumor types (10) (11) (12) . In node-negative breast cancer, we demonstrated that P53 expression and S-phase cell fraction, as evaluated by [ 3H]-thymidine incorporation ([ 3H]-thymidine labeling index; [ 3H]-dT LI), provided independent information for longterm prognosis (11) . Conversely, the prognostic information provided by Bcl-2 expression, which negatively controls apoptosis, was markedly dependent on PS3 expression (13) . These findings suggest that P53 is involved in cell functions other than proliferation control.
Although there is evidence for a discrete correlation between P5 3 expression and [3H]-dT LI or bromodeoxyuridine labeling index in breast cancer (11, (14) (15) (16) , no previous studies have simultaneously assessed P53 staining and [3H]-dT labeling in paraffinembedded tissue. To address this issue, we have developed a doublelabeling technique that can stain for P53 and [3H]-dT on 4-pm sections from paraffin-embedded breast cancer specimens. The possibility to discriminate the two labelings on individual cells is made feasible by the different pictures provided by immunohistochemical and autoradiographic techniques. 
Materials and Methods
The study was performed on 44 breast cancers from previously untreated patients who underwent surgery at the Istituto Nazionale Tumori of Milan. The tumors were known to be P53-positive (P53'. i.e., with more than 5% positive cells) by immunohistochemistry and were selected from a series of 300 cancers previously characterized for several biological parameters (17) .
In Vitro Determinations. Immediately after surgery, part of the tumor material was processed for the determination of [ 'HIIT L1 and P53 expression (11) and part was frozen and stored at -80°C for side studies (i.e.. hormone receptor determination according to the dextran-coated charcoal technique) (18) .
Incubation with [3H]-Thymidine. Tumor material, sampled by the pathologist from different areas, was cleansed of fat and necrotic tissues and minced into fragments of a few mm3. Samples containing 10-15 pooled fragments were incubated for 1 hr at 37'C with ['HI-thymidine by using a commercial kit (Ribbon; Milan. Italy). Complete culture medium. freshly reconstituted, contained 199 medium, 20% fetal calf serum, antibiotics, and 6 p G of [ 3H]-thymidine (222 KBqlml; specific activity 185 GBqlmmol).
At the end of the incubation period, the specimens were fixed for 6 hr in buffered formalin and subjected to the conventional histological procedures.
Double Detection T&que.
Double labeling with ['HI-dT and PAbl801 was determined on the same 4-wm histological sections from formalin-fuced. paraffin-embedded blocks (Figure 1 ). Sections were treated with a solution of 3% HzOz to quench endogenous peroxidase activity and then incubated in a solution of 3% bovine serum albumin to block nonspecific protein binding. Finally, sections were incubated for 1 hr at room temperature with a 1:50 dilution of PAbl801 (Oncogene Science; Manhasset. NY). an MAb raised against human P53 that recognizes both wild-type and mutant forms of P53 protein. After incubation the sections were processed by the ABC immunoperoxidasc system (Vectastain kit; Vector Laboratories, Burlingame, CA) according to the manufacturer's recommendations (11) . Negative controls were obtained by omission of the primary an ti body.
To avoid chemical interactions by reagents used for P53 detection with the photographic emulsion. slides were washed overnight in distilled water and dipped in a solution of 0.5% gelatin before the autoradiographic prom dure (19) . Slides were dipped in a photographic emulsion (Ilford K5; 11ford, London, UK). After exposure for 3 days at 4"C, autoradiographs were developed in Ilford Phenprint for 6 min at 19'C and fixed in Hypam compound for 10 min. Samples were stained with hematoxylin and eosin at 4°C.
Analysis ofData. Dfirent criteria were adopted for independent evaluation of the two markers on consecutive histological sections. The score for P53 was performed through the entire section. whereas labeling for ['HI-dTwas limited to the peripheral area (usually up to 80 pm in depth). considering the relative penetration of the precursor. Conversely. for double detection on a single section, evaluation of both markers was limited to peripheral areas after a preliminary analysis showed for P53 a significant concordance (p = 0.0001) between the two scoring criteria.
[ 'H]-dT-Iabelcd and P53' cells were quantified independently by two observers by scoring more than 3000 tumor cells for each tumor. Patterns 
tion of cells with: (a) nuclear labeling for [3H]-dT and P53, (3)/[(1) + (2)

+ (3)) x 100; and (b) only P53 labeling, (l)/[(l) + (2) + (3)] x 100. The relation between P53 expression and [3H]-dT LI on different sec-
tions and on the same section, and their association within different biological and pathological subsets, were analyzed by evaluating Spearman's rank correlation coefficient (7,) .
Results
On this selected series of P53+ tumors, P53 expression and [3H]-dT LI, as determined on different sections, appeared significantly and directly related but with a poor correlation coefficient ( Table  1) . When such a relation was analyzed as a function of pathological and biological features indicative of clinical aggressiveness for this tumor type, this low although significant correlation held true within subsets homogeneous for tumor size (smaller or larger than 2 cm) and for axillary lymph nodal involvement (absent or present), as well as within estrogen receptor-positive (ER+) tumors. Conversely, no relation between P53 expression and [3H]-dT LI was observed in estrogen receptor-negative (ER-) tumors.
When P53 expression and [3H]-dT labeling were analyzed by the dual technique, less than 40-50% of the tumor cells exhibited double nuclear labeling. On the whole, the poor correlation observed on individual tumors by analysis on different sections (Table 1) was also maintained on single cells. In fact, only 37% of the total number of cells that incorporated [3H]-dT were P53+, and the fraction of [3H]-dT-labeled cells within P53+ was even lower (10./0). These quantitative data are supported by the findings shown in Figure 1 , which clearly shows that only one of the P53immunopositive cells incorporated [3H]-thymidine, i.e., was actively proliferating.
In successive analyses, the fraction of double-labeled cells or the fraction of only P53+ cells was analyzed in relation to [3H]-dT LI of the corresponding tumor, which was used as an indicator of proliferative behavior. There was direct and significant proportionality between the fraction of cells positive for P53 and [3H]-dT and the tumor proliferative rate (Figure 2) . In fact, the fraction of doublelabeled cells increased with increasing [3H]-dT LI. Such a relation was consistently observed within subsets of tumors comparable for size and nodal status and within ER+ tumors (rJ = 0.7-0.9), and it was lower in ER-tumors (r, = 0.5). Again, there was a significant Table 1 
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proportionality between the fraction of cells positive to only P53 and tumor proliferative rate, but the relation was inverse (Figure  3) . The number of P53+ cells decreased with increasing [3H]-dT LI. This finding was independent of tumor size, lymph node involvement, or ER status (rJ = -0.7 to -0.6).
Discussion
Experimental and clinical evidence about human solid tumors, including breast cancer, supports a partial independence between the accumulation of €53 protein (which in normal cells is involved in the regulation of proliferation checkpoints of the cell cycle) and the proliferative rate of a tumor cell population, directly evaluated by functional markers such as [3H]-dT LI or BrdU LI (llJ5-17) .
In addition, involvement of the TP53 gene in cell functions other . 5 10 15 3H-dT LI than proliferation control was indirectly confirmed by the marked biological and clinical concordance of information provided by P> 3 accumulation and that of other markers, such as Bcl-2 expression (13) . The latter is one of the factors involved in the regulation of apoptosis, i.e., programmed cell death. However, all of these observations have been derived by independent evaluation of the different biological markers on serial cross-sectional samples. Such an approach is clearly open to the criticism that different cells, or cell clusters, could be examined in the different sections. Only a doublelabeling technique on the same specimens can avoid this bias and help to define the independence between markers that have been believed to be involved in the same biological phenomenon.
A double-labeling technique was developed to detect the nuclear co-localization of P53 staining and [3H]-dT incorporation on individual cells in paraffin-embedded tissue. Breast cancer was chosen because previous studies on this tumor type had shown a complex interdependence between P53 and cell proliferation (11~3-16). In this technical approach, the availability of different and compatible methodologies, such as autoradiography and immunohistochemistry, provided easily distinguishable pictures for the two markers.
Such a study was obviously performed on a series of P53' tumors. Even in these selected cases, the degree of concordance between P53' cells and [3H]-dT LI, as evaluated on different sections, was poor in the overall series and in the different biological and pathological subsets and was minimal in ER-tumors. Even the co-prescence of P53 accumulation and [3H]-dT incorporation in individual cells was generally low, but it increased with the proliferative status of the tumor. The evidence for a direct proportionality between double-labeled cells and tumor proliferative rate indicates a causative effect between P53 accumulation and proliferative stimulus, which held true for all the tested biological and pathological situations except for ER-status. For this last subset, the involvement of other factors, autocrine or paracrine, in supporting proliferation could be hypothesized.
The occurrence of a very low fraction of P53' cells within [3H]-dT-incorporating cells was first explained by the evidence that [ 3H]-dT-labeled cells represent only a fraction of the proliferating cell compartment. However, the finding of an inverse relationship between the fraction of cells positive only to P53 and the tumor proliferative rate should support involvement of the p53 gene in cell functions not directly producing a proliferation stimulus. In addition, this finding represents direct evidence that, at a cellular level, P5 3 accumulation and proliferative rate are partially independent and that tumor proliferation is clearly controlled by factors other than P53 status. This finding reinforces the importance of investigating genetic alterations and control mechanisms that determine the overall proliferative rate in experimental and clinical tumors.
